• LAST PRICE
    16.0100
  • TODAY'S CHANGE (%)
    Trending Up0.2100 (1.3291%)
  • Bid / Lots
    15.8100/ 3
  • Ask / Lots
    16.6300/ 2
  • Open / Previous Close
    16.3200 / 15.8000
  • Day Range
    Low 15.8100
    High 17.4139
  • 52 Week Range
    Low 8.7200
    High 30.4300
  • Volume
    6,554
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 15.8
TimeVolumeGHRS
09:32 ET143617.14
09:39 ET31416.38
10:03 ET11616.87
10:06 ET110015.81
10:10 ET10016.41
10:12 ET40016.15
10:15 ET60016.14
10:17 ET85716.01
10:21 ET70016.01
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGHRS
GH Research PLC
821.9M
-39.4x
---
United StatesTIL
Instil Bio Inc
824.9M
-4.6x
---
United StatesVTYX
Ventyx Biosciences Inc
813.6M
0.0x
---
United StatesCTIC
CTI Biopharma Corp
809.6M
-5.9x
---
United StatesIGMS
IGM Biosciences Inc
805.0M
-3.7x
---
United StatesCMPS
Compass Pathways PLC
853.2M
-10.3x
---
As of 2022-08-08

Company Information

GH Research PLC is a clinical-stage biopharmaceutical company. The Company is engaged in offering treatment for psychiatric and neurological disorders. It focuses on developing its 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), therapies for the treatment of patients with Treatment-Resistant Depression (TRD). Its portfolio includes GH001, its inhalable 5-MeO-DMT product candidate which is delivered via a vaporization device produced by a third party, and GH002, its injectable 5-MeO-DMT product candidate. The Company is developing its 5-MeO-DMT product candidates, GH001 and GH002, in its focus area of psychiatric and neurological disorders. Its lead program, GH001, is in the Phase II part of an ongoing Phase I/II clinical trial in patients with TRD. The 5-MeO-DMT is a serotonergic psychedelic, a class of psychoactive drugs that act through an agonist action on serotonin receptors and cause an altered state of consciousness.

Contact Information

Headquarters
28 Baggot StreetDublin, Ireland 2D02 NX43
Phone
---
Fax
---

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$821.9M
Revenue (TTM)
$0.00
Shares Outstanding
52.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-0.41
Book Value
$5.33
P/E Ratio
-39.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.